Answers are grounded in this paper and cite their sources.
Randomized double-blind trial shows reduced spleen size and improved survival with ruxolitinib in myelofibrosis, highlighting clinical benefit despite early anemia and thrombocytopenia.
Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).
No takes yet. Share an insight, caveat, or question.
Verstovšek et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: